Thus, clarifying controls on VCP nuclear translocation during spermatogenesis may not only identify entry points for treating forms of male infertility, including non-obstructive azoospermia, but may also reveal novel targets for treating VCP-related degenerative diseases. This evidence concerns the gene VCP and neurodegenerative disease.